Latest Headlines

  1. Biocartis NV: Biocartis Receives FDA Approval For The Idylla™ CDx MSI Test 9/15/2025

    Biocartis Group of Companies (“Biocartis”), an innovative molecular diagnostics company, is pleased to announce that its Idylla™ CDx MSI Test developed in partnership with Bristol Myers Squibb, has received the first-ever Premarket Approval (PMA) from the FDA for a cartridge-based, fully automated, “sample-to-result” companion diagnostic test.

  2. LabConnect And OmniScience To Deliver First Agentic AI Solution For Real-Time Clinical Trial Lab Insights 9/15/2025

    LabConnect, a leading global provider of central laboratory services today announced plans to form a strategic collaboration with OmniScience, the AI company behind Vivo, the first agentic AI control tower for clinical trials.

  3. Genesee Scientific Acquires Jade Scientific, Expanding Capabilities In Lab Essentials Market 9/15/2025

    Genesee Scientific, a leading provider of high-quality, value-driven lab essentials, today announced the acquisition of Jade Scientific, a Michigan-based distributor recognized for its extensive offering of chemicals and consumables to clinical reference, pharma/biotech, and environmental labs nationwide.

  4. OmniPathology And Delta Labs Announce International Collaboration To Expand Access To Proprietary Oropharyngeal HPV Swab Testing 9/15/2025

    OmniPathology, a U.S.-based advanced molecular diagnostics laboratory, today announced a new international collaboration with Delta Medical Laboratories, a leading clinical laboratory provider in Saudi Arabia.

  5. Voicebrook And Gestalt Diagnostics Announce Seamless Integration To Enhance Pathology Workflows 9/11/2025

    Voicebrook, Inc., the leading provider of pathology reporting solutions, today announced a new integration with Gestalt Diagnostics, a leader in digital pathology solutions.

  6. Precision BioLogic Leads The Way In Hemophilia Testing 9/10/2025

    Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the expanded utility of its CRYOcheck Chromogenic Factor VIII assay in anticipation of emerging hemophilia treatments such as Mim8, a next generation bispecific antibody for the treatment of hemophilia A.

  7. QIAGEN Secures European CE-IVDR Certification For Full QIAstat-Dx Portfolio 9/10/2025

    QIAGEN today announced that it has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel that sets a new benchmark in the diagnosis of central nervous system (CNS) infections.

  8. Prinses Máxima Center For Pediatric Oncology Implements Callisto™ From Volta Labs To Streamline Clinical Genomics Workflows 9/10/2025

    Volta Labs today announced that the Prinses Máxima Center for Pediatric Oncology has acquired the Callisto™ platform to streamline sample preparation across multiple genomics workflows, supporting both Illumina and Oxford Nanopore Technologies (ONT) sequencing platforms.

  9. Exact Sciences Launches Cancerguard™, First-Of-Its-Kind Multi-Cancer Early Detection Blood Test 9/10/2025

    Exact Sciences Corp. a leader in cancer diagnostics, today announced the launch of the Cancerguard test, a new multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States.

  10. OptraSCAN To Introduce HER2 Scan + Analyze Pilot At CAP 2025 9/9/2025

    OptraSCAN, a leader in digital pathology and AI-powered diagnostics, today announced the launch of its HER2 Scan + Analyze Quantitative Solution Pilot Program at the College of American Pathologists (CAP) 2025 - The Pathologists’ Meeting, running September 13-16 in Orlando, Florida.